Europe has the science, talent and clinical ambition to remain a global leader in advanced therapies. The harder question is whether its regulatory environment can move with the same urgency.
That question sat at the heart of this Advanced Therapies Europe discussion on the future of ATMP regulation. The debate was not about choosing between speed and scrutiny. It was about building a system capable of delivering both.
For developers, regulators and patients, the stakes are significant. Regulatory fragmentation does more than create administrative complexity. It adds cost, delays decisions and can influence where companies choose to run trials, seek approval and launch therapies.
The opportunity, therefore, is not simply to rewrite Europe’s rulebook. It is to create greater trust in how that rulebook is executed.
Fragmentation is now a competitiveness issue
Europe has spent years building a common regulatory framework, yet developers can still experience meaningful variation across countries.
Different interpretations, national requirements and inconsistent expectations can make one market feel like several. For advanced therapies, where development programmes are already complex, capital-intensive and often focused on small patient populations, that friction matters.
The panel made clear that Europe’s competitiveness depends on closing the gap between harmonisation in principle and harmonisation in practice.
Other markets are evolving quickly. The US, UK and China are refining pathways intended to attract innovation and accelerate development. In that context, predictability becomes a strategic advantage.
Companies need to know not only what the rules are, but how they will be applied.
Smarter evidence, not lower standards
One of the strongest themes from the discussion was that regulatory acceleration should not be confused with regulatory compromise.
The better question is where unnecessary duplication can be removed.
Advanced therapies do not always fit traditional development models, particularly in rare and serious diseases where patient populations are small and evidence generation can be difficult. A more proportionate system must distinguish between genuine uncertainty and procedural repetition.
That includes making better use of high-quality evidence generated elsewhere.
If credible data already exist, geography alone should not reduce their value. Greater regulatory reliance, stronger international alignment and more confidence in shared evidence could reduce the need to recreate studies simply to satisfy different jurisdictions.
Real-world data, modelling and digital approaches could also support more efficient evidence generation, provided scientific standards remain robust.
The objective is not less evidence. It is better use of evidence.
Regulatory strategy has to start earlier
For developers, one of the most practical messages from the panel was simple: start with the end in mind.
Robert Allen compared regulatory development to a chess game. Companies need to understand where they ultimately want their product to reach, which regulatory systems they will need to navigate and what decisions made today could restrict those options later.
That means regulatory strategy cannot sit at the end of development.
Choices around clinical design, manufacturing, comparability and evidence generation should be made with future markets in mind from the outset. A programme designed around one jurisdiction may appear efficient early on but encounter avoidable barriers when expansion begins.
Early engagement with regulators can help expose those differences before they become expensive.
Regulators must become enablers of execution
The discussion also pointed toward a broader shift in the role of regulators.
The regulator of the future cannot operate solely as a final gatekeeper. It must increasingly act as an enabler of development by providing earlier clarity, connecting regulatory and health technology assessment perspectives, and helping innovators understand what credible evidence will ultimately be required.
That does not weaken regulatory independence. It strengthens execution.
For Europe, this mindset could prove as important as legislative reform itself.
The real measure of success is patient access
The purpose of regulatory reform is not administrative elegance. It is to help safe, effective and high-quality therapies reach patients.
A more predictable ATMP environment could reduce unnecessary development costs, improve investor confidence, attract more clinical research and give companies greater reason to launch in Europe.
The next phase of Europe’s regulatory evolution should therefore be judged by outcomes.
Can developers navigate the system with greater certainty? Can strong evidence be reused rather than unnecessarily repeated? Can regional differences be identified earlier? Can therapies move through development faster without compromising standards?
If the answer becomes yes, Europe will have achieved something more valuable than simplification.
It will have created trusted execution.
)